From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection [Pharmacology]

The HIV-1 pandemic affecting over 37 million people worldwide continues, with nearly one-half of the infected population on highly active antiretroviral therapy (HAART). Major therapeutic challenges remain because of the emergence of drug-resistant HIV-1 strains, limitations because of safety and toxicity with current HIV-1 drugs, and patient compliance for lifelong,...

http://ift.tt/2BqfILq